The Chemours Company Provides Update on Second Quarter 2025 Outlook
1. Chemours expects TSS net sales to rise 25% due to Opteon™ demand. 2. APM anticipates a 25% sequential increase in Adjusted EBITDA for Q2 2025. 3. TT's Adjusted EBITDA may decline 15% due to operational disruptions at U.S. sites. 4. Overall, consolidated net sales expected at the high end of original projections. 5. Corporate costs are projected to increase due to legacy litigation ongoing in New Jersey.